BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-revmed-daraxonrasib-pdac-fda-submission-window-2026@catalyst-calendar.local
DTSTAMP:20260720T200641Z
DTSTART:20260624T130000Z
DTEND:20260624T133000Z
SUMMARY:Revolution Medicines daraxonrasib胰腺癌NDA提交与CNPV路径窗口
DESCRIPTION:Revolution Medicines在RASolute 302三期中报告daraxonrasib相较化疗显著改善PFS和OS，并表示拟向全球监管机构提交数据，包括通过FDA Commissioner’s National Priority Voucher计划提交NDA。\\nImpact score: 78\\nExpected: 公司提交NDA或更新监管路径，可能影响RAS(ON)抑制剂、胰腺癌治疗和FDA国家优先审评券路径的投资者预期。\\nAffected: RVMD(subject\, unknown\, score 88)\; XBI(etf\, mixed\, score 55)\; BNTX(peer\, mixed\, score 45)\; MRK(peer\, mixed\, score 42)\\nSources: Revolution Medicines Q1 2026 update: https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-first-quarter-2026-financial\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-revmed-daraxonrasib-pdac-fda-submission-window-2026
CATEGORIES:filing\,US\,RAS inhibitor\,pancreatic cancer\,NDA\,CNPV\,FDA
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Revolution Medicines daraxonrasib胰腺癌NDA提交与CNPV路径窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Revolution Medicines daraxonrasib胰腺癌NDA提交与CNPV路径窗口
END:VALARM
END:VEVENT
END:VCALENDAR